Bardet-Biedl Syndrome
New Bardet-Biedl syndrome research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), setmelanotide evidence expanded into matched and real-world reports with variable hunger and weight responses, alongside updated diagnostic criteria and gene-first identification approaches. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Setmelanotide results. Moved from matched comparison to varied real-world follow-up.
- Metabolic and daily life. Clinic cohorts detailed adolescent metabolic strain and adult functioning.
- Kidney and blood pressure. Small follow-ups linked early kidney findings with ongoing BP tracking.
- How BBS is diagnosed. Consensus criteria and gene-first approaches increased diagnostic clarity.
- What lab studies suggest. Models linked specific variants to distinct cellular disruptions.
New
September 2026
- Hunger and weight changes. Setmelanotide effects on hunger and weight differed across people.
- Kidney transplant stability. One report of two children noted stable transplant kidney function during treatment.
- Genetic cause found. One study identified causative or potentially causative gene variants in all 26 participants, including some variants of uncertain significance.
August 2026
- Setmelanotide outcomes. After starting it, weight measures and HbA1c were lower.
- Hormone lab changes. Several hormone lab signals changed, then stayed stable.
- Metabolic risk score. A simple blood-fat and BMI score flagged teen metabolic syndrome.
- Care pathways. A European consensus supported expert centers and structured care pathways.
July 2026
- Hunger severity ratings. Interviews found more severe hunger than short questionnaires.
- Symptom interview effects. Talking through symptoms often led to higher hunger severity ratings.
- New genetic findings. Two case reports described additional gene variants and inheritance patterns.
June 2026
- Genetic testing. Genetic testing identified more BBS cases than symptom checklists.
- Kidneys and blood pressure. Some children had early kidney changes with stable function.
- Follow-up plan. A framework organized follow-up across many body systems.
May 2026
- Diagnosis criteria. New consensus criteria describe a clinical route and a genetics-supported route to define Bardet-Biedl syndrome diagnosis more consistently.
- Physical and social functioning. In a small adult study, average physical and social quality-of-life scores were lower than general population norms.
- Planning and depression. In that study, a smaller group had impaired planning and organization scores, and these difficulties were reported alongside recent depression.
April 2026
- Weight and growth in teens. In one pediatric clinic cohort, obesity was common in adolescence, and some teens also had short stature.
- High triglycerides. Raised triglycerides were frequently reported, consistent with ongoing metabolic strain.
- Setmelanotide: skin darkening. A single case report described diffuse skin darkening during setmelanotide treatment, without showing how often this occurs.
March 2026
- Earlier diagnosis. More disruptive (truncating) gene changes were linked with being diagnosed at a younger age in a small genetically confirmed group.
- Kidney changes. In that same small group, kidney abnormalities were reported only in people with truncating gene variants.
- Differences within families. Reports of sibling pairs showed that Bardet-Biedl syndrome features can differ widely even within the same family.
- Appetite pathway clues. Early protein modeling work suggested possible links between some BBS proteins and appetite and metabolism signaling.
February 2026
- Setmelanotide and weight change. In a 52-week comparison, people on setmelanotide showed larger weight-related changes than a matched usual-care group, with uncertainty because the groups were not randomly assigned.
- Diagnosis can change with time. Some early signs that looked like BBS were later linked to other genetic conditions, showing that the diagnosis may shift as more features appear and testing expands.
- New gene variants in lab models. New TTC8 and BBS7 variants were studied in computer models and kidney-like cells, suggesting effects on cilia-related biology but not directly changing near-term care.
January 2026
- BBS1 variants and vision. In one clinic group, different BBS1 variant patterns were linked to different visual acuity, which may help explain why vision can vary even among people with BBS1.
- Pituitary changes in mice (BBS4). In mice, loss of the BBS4 gene was linked to a smaller pituitary gland and a different balance of hormone-producing cells, which is background biology rather than patient outcome evidence.
- Early genetic confirmation. A single infant case report showed that early-onset obesity plus other features can lead to early genetic confirmation of BBS, but it did not report treatment results.
Get the monthly update by email
Subscribe here to receive an email when a new monthly Bardet-Biedl syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).